Exelixis (EXEL) 5.55 0.00

Exelixis, Inc.
(EXEL) 5.55 0.00

Last Trade:	4.59	Day Range:	4.58 - 4.8199
Trade Time:	08:05PM	52wk Range:	3.94 - 11.68
Prev. Close:	4.59	Market Cap:	681.51M
Open:	4.66	Div Yield:	0
Volume:	2284100	PE:
EPS:	0.60

The Latest On EXEL

Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Medullary Thyroid Cancer 5/30/12 6:33am

Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men With Advanced Prostate Cancer 5/30/12 6:29am

Prostate Cancer Companies Suffer When They Ignore Urologists 5/22/12 11:47am

Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration 5/3/12 6:50am

UPDATE: Stifel Nicolaus Resumes Buy, $8 PT on Exelixis 3/15/12 11:41am

Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer 3/5/12 7:44am

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio 2/21/12 4:00am

A Peek Into The Market Before The Trading Starts 2/10/12 8:23am

Exelixis Announces Pricing of $60.5 Million Public Offering at $5.50 per Share 2/10/12 7:44am

Exelixis Announces Proposed Public Offering of 10M Shares 2/9/12 5:09pm

Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma 1/20/12 3:45pm

JPMorgan Confab Kicks Off Biotech 2012 1/5/12 12:46pm

Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Medullary Thyroid Cancer 5/30/12

Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men With Advanced Prostate Cancer 5/30/12

Prostate Cancer Companies Suffer When They Ignore Urologists 5/22/12

Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration 5/3/12

UPDATE: Stifel Nicolaus Resumes Buy, $8 PT on Exelixis 3/15/12

Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer 3/5/12

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio 2/21/12

A Peek Into The Market Before The Trading Starts 2/10/12

Exelixis Announces Pricing of $60.5 Million Public Offering at $5.50 per Share 2/10/12

Exelixis Announces Proposed Public Offering of 10M Shares 2/9/12

Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma 1/20/12

JPMorgan Confab Kicks Off Biotech 2012 1/5/12

Prostate Cancer Companies Suffer When They Ignore Urologists 5/22/12

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest PEG Ratio 2/21/12

Exelixis Trading Higher After Licensing Agreement with Merck 12/21/11

Biotech/Pharma Stocks Trading News Alert: Aethlon Medical, OXiGENE, Adventrix, Chelsea Therapeutics, Exelixis 8/10/11

Mad Money Lightning Round: Cramer Likes PPL Corp 8/1/11

Top Percentage Gainers and Losers as of 2pm 06/07/11 6/7/11

Top Percentage Gainers and Losers as of 12pm 06/07/11 6/7/11

Mad Money Lightning Round: Cramer Likes Exelixis (HELE, EXEL, DCTH, BKS, AMZN) 4/27/11

Top Percentage Gainers And Losers As Of 10 a.m. 4/12/2011 (CYH, THC, SKH, JPM, EXEL, GS, TIBX, HPQ, SIFY, WMS, GFRE, EXTR, SB, AIB, CCRT, GIL, THLD, BRNC, SIMG) 4/12/11

Top Percentage Gainers And Losers As Of 8:45 a.m. 4/12/2011 (EXEL, GS, KITD, CYH, CBLI, LVLT, UBS, EXTR, AA, BBL, F, BP) 4/12/11

Puts Purchased on Exelixis, Inc. (EXEL) 3/15/11

Stocks on the Move:(EXEL) New Year High 2/28/11

UPDATE: Stifel Nicolaus Resumes Buy, $8 PT on Exelixis 3/15/12

Jefferies Maintains Hold Rating and $6 PT on Exelixis 12/2/11

Piper Jaffray Maintains Neutral, $5 PT on Exelixis 12/2/11

Piper Jaffray Neutral on Exelixis 11/14/11

End-of-Day Market Summary for November 1, 2011 11/1/11

UPDATE: Piper Jaffray Downgrades Exelixis to Neutral 11/1/11

Jefferies Maintains Hold Rating and $6 PT on Exelixis 11/1/11

Goldman Sachs Lowers PT on Exelixis to $6 11/1/11

Piper Jaffray Downgrades Exelixis to Neutral, PT Lowered to $5 11/1/11

UPDATE: J.P. Morgan Lowers Price Target on Exelixis to $5 11/1/11

JP Morgan Lowers PT on Exelixis to $5 11/1/11

Jefferies Initiates Coverage on Exelixis with Hold Rating 9/20/11

Trade EXEL
NOW!

Partner Headlines

Tuesday's Top Prospects (& Why): EXEL, EMAN, NBS 5/30/12

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 5/17/12

ASCO '12 Abstract Dump: Cancer Stocks in Focus 5/16/12

Friday's Top 10 Articles, Videos on TheStreet 5/4/12

Biotech Stock Mailbag: Exelixis, Protalix, Arena 5/4/12

Exelixis Inc. Reports Operating Results (10-Q) 5/3/12

10 Stocks That Could Rise in Market Decline 4/10/12

'Mad Money' Lightning Round: Bullish on Baxter 3/27/12

Press Releases

Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival in Men With Advanced Prostate Cancer 5/30/12 Business Wire

Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Medullary Thyroid Cancer 5/30/12 Business Wire

Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting 5/16/12 Business Wire

Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference 5/10/12 Business Wire

Exelixis Announces First Quarter 2012 Financial Results 5/3/12 Business Wire

Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration 5/3/12 Business Wire

Exelixis Announces May 8th Webcast of Presentation at the Deutsche Bank Securities 37th Annual Health Care Conference 5/2/12 Business Wire

Exelixis Announces May 3rd Webcast of First Quarter 2012 Financial Results Conference Call 4/19/12 Business Wire

Cabozantinib to be Featured in Nine Presentations at 2012 ASCO Annual Meeting 4/2/12 Business Wire

Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib and Abiraterone in Men With Castration-Resistant Prostate Cancer 3/5/12 Business Wire

Exelixis Announces March 6 Webcast of Presentation at the Cowen Health Care Conference 3/1/12 Business Wire

Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis 2/24/12 Business Wire

Get the latest EXEL stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Exelixis, Inc. stock price.

Exelixis, Inc. by YCharts

Exelixis (EXEL) 5.55 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On EXEL

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social